| Literature DB >> 26979583 |
Alexander Mok1, Sumanto Haldar1, Jetty Chung-Yung Lee2, Melvin Khee-Shing Leow1,3,4, Christiani Jeyakumar Henry5,6,7.
Abstract
BACKGROUND: Cardio-Metabolic Disease (CMD) is the leading cause of death globally and particularly in Asia. Postprandial elevation of glycaemia, insulinaemia, triglyceridaemia are associated with an increased risk of CMD. While studies have shown that higher protein intake or increased meal frequency may benefit postprandial metabolism, their combined effect has rarely been investigated using composite mixed meals. We therefore examined the combined effects of increasing meal frequency (2-large vs 6-smaller meals), with high or low-protein (40 % vs 10 % energy from protein respectively) isocaloric mixed meals on a range of postprandial CMD risk markers.Entities:
Keywords: Cardiometabolic disease risk; High protein; Meal frequency
Mesh:
Substances:
Year: 2016 PMID: 26979583 PMCID: PMC4793530 DOI: 10.1186/s12937-016-0141-5
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Participant’s characteristics
| Range | |||
|---|---|---|---|
| Characteristic | Mean (SD) | Min | Max |
| Age (Years) | 28.8 (6.6) | 22 | 40 |
| Height (m) | 1.76 (0.04) | 1.71 | 1.84 |
| Body Mass (kg) | 68.2 (7.8) | 58.1 | 83 |
| Body Mass Index (kg/m2) | 21.9 (1.7) | 19.5 | 24.5 |
| Umbilical Waist Circumference (cm) | 80.5 (7.9) | 70 | 92 |
| Body Fat % | 17.0 (4.7) | 8.9 | 22.6 |
| Systolic Blood Pressure (mmHg) | 120.4 (5.7) | 113 | 130 |
| Diastolic Blood Pressure (mmHg) | 76.1 (6.4) | 65 | 85 |
Fig. 1Study Protocol: For each dietary condition, participants came to the clinical trial facilities on 2 consecutive days. The day before the main trial day was for the insertion of a continuous glucose monitor and the consumption of a standardized evening meal. On the main trial day, BP and venous blood samples were collected at regular intervals, as shown, for up to 8.5 h following the first meal of each dietary condition
Nutritional information of test-meals
| CON-2, CON-6 dietary conditions | |||
| Meal Constituents: Breakfast – White Bread (171 g), Margarine (30 g), Malted Cocoa Drink (375 g) | |||
| Lunch – Chicken Soup Noodles (225 g), Cashew Nuts (30 g) | |||
| Breakfast | Lunch | Total | |
| Energy (kcal) | 889 | 1127 | 2016 |
| Protein (g) | 23 g (10 %) | 26 g (9 %) | 49 (10 %) |
| Carbohydrate (g) | 130 g (57 %) | 134 g (42 %) | 264 (52 %) |
| Fat (g) | 32 g (33 %) | 53 g (49 %) | 85 (38 %) |
| Estimated Glycaemic Index | 73.4 | 50.3 | 61.7 |
| PRO-2, PRO-6 dietary conditions | |||
| Meal Constituents: Breakfast – Milk (300 g), Ice-Cream (150 g), Whey powder (91.2 g), Cashew Nuts (30 g), Lunch – Braised Chicken (330 g), Prawn Dumplings (120 g), Malted Cocoa Drink (375 g) | |||
| Breakfast | Lunch | Total | |
| Energy (kcal) | 910 | 998 | 1908 |
| Protein (g) | 89 g (39 %) | 90 g (36 %) | 179 (38 %) |
| Carbohydrate (g) | 66 g (30 %) | 75 g (31 %) | 141 (30 %) |
| Fat (g) | 31 g (31 %) | 37 (33 %) | 68 (32 %) |
| Estimated Glycaemic Index | 37.1 | 24.9 | 30.6 |
Macronutrient information obtained from nutrition labels on constituent foods
Fig. 2Postprandial responses over time (left); Incremental Areas Under the Curve (Right). Error bars are standard error of the mean (SEM)
Postprandial responses across time
| Time (h) | 0 | 1 | 2.5 | 4 | 5.5 | 7 | 8.5 | iAUC | Overall p (Diet) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Glucose (mmol/L) | ||||||||||
| CON-2 | 4.7 ± 0.6 | 6.1 ± 1.1a | 5.4 ± 0.6a | 4.8 ± 0.8a | 6.8 ± 1.0a | 5.7 ± 0.5 | 5.4 ± 0.8 | 536 ± 290 | .003 | |
| CON-6 | 5.0 ± 0.8 | 6.2 ± 1.1 | 5.9 ± 0.5b | 5.8 ± 0.6b | 6.1 ± 0.5a | 5.7 ± 0.7a | 6.1 ± 1.1 | 480 ± 292 | - 0.19 | |
| PRO-2 | 4.8 ± 0.4 | 5.2 ± 0.4b | 5.0 ± 0.4a | 4.9 ± 0.4a | 5.2 ± 0.6b | 5.2 ± 0.7 | 5.0 ± 0.8 | 185 ± 166 | - 1.21 | |
| PRO-6 | 4.7 ± 0.4 | 5.2 ± 0.4 | 5.0 ± 0.4a | 5.1 ± 0.4a | 5.1 ± 0.5b | 5.1 ± 0.6b | 5.2 ± 0.7 | 214 ± 188 | - 1.11 | |
| Insulin (μU/ml) | ||||||||||
| CON-2 | 6.1 ± 3.3 | 84.3 ± 45.3a | 74.0 ± 43.6a | 21.6 ± 16.8 | 105.6 ± 61.0a | 62.0 ± 46.4 | 28.6 ± 17.9 | 28.4 ± 15.6 a | .001 | |
| CON-6 | 8.1 ± 5.0 | 49.7 ± 19.5 | 60.1 ± 31.9 | 45.6 ± 29.2a | 53.7 ± 33.2 | 39.5 ± 22.0 | 44.8 ± 24.9 | 19.8 ± 10.3 | - 0.57 | |
| PRO-2 | 6.0 ± 4.2 | 63.3 ± 41.2 | 58.7 ± 36.2 | 25.6 ± 18.5b | 46.6 ± 22.5 | 34.4 ± 24.9 | 27.8 ± 25.9 | 18.1 ± 10.6 | - 0.68 | |
| PRO-6 | 7.1 ± 3.6 | 47.6 ± 28.4b | 39.4 ± 21.3b | 30.8 ± 16.3 | 34.6 ± 12.6b | 28.3 ± 15.4 | 36.0 ± 25.0 | 13.7 ± 7.1b | - 0.97 | |
| TAG (mmol/L) | ||||||||||
| CON-2 | 0.9 ± 0.3 | 1.2 ± 0.4 | 1.6 ± 0.6 | 1.5 ± 0.6 | 1.6 ± 0.5 | 1.4 ± 0.6 | 1.6 ± 0.4 | 294 ± 133 | .026 | |
| CON-6 | 1.1 ± 0.5 | 1.1 ± 0.5 | 1.4 ± 0.5 | 1.6 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.5 | 1.8 ± 0.6 | 224 ± 139 | - 0.52 | |
| PRO-2 | 0.9 ± 0.3 | 1.1 ± 0.3 | 1.6 ± 0.6 | 1.5 ± 0.4 | 1.7 ± 0.6 | 1.7 ± 0.5 | 1.7 ± 0.6 | 322 ± 91 | 0.21 | |
| PRO-6 | 1.0 ± 0.5 | 1.2 ± 0.5 | 1.6 ± 0.6 | 1.9 ± 0.8 | 1.9 ± 0.7 | 1.9 ± 0.7 | 2.0 ± 0.7 | 340 ± 175 | 0.34 | |
| hs-CRP (mg/L) | ||||||||||
| CON-2 | 0.74 ± 1.41 | 0.79 ± 1.44 | - | 0.74 ± 1.44 | 0.69 ± 1.39 | - | 0.72 ± 1.40 | −0.5 ± 90 | .17 | |
| CON-6 | 0.80 ± 1.04 | 0.81 ± 1.00 | - | 0.73 ± 0.87 | 0.66 ± 0.81 | - | 0.55 ± 0.70 | −50 ± 115 | - 0.55 | |
| PRO-2 | 0.64 ± 0.86 | 0.69 ± 0.84 | - | 0.70 ± 0.82 | 0.65 ± 0.77 | - | 0.63 ± 0.71 | 12 ± 71 | 0.14 | |
| PRO-6 | 0.12 ± 0.18 | 0.13 ± 0.21 | - | 0.15 ± 0.23 | 0.18 ± 0.24 | - | 0.17 ± 0.25 | 19 ± 35 | 0.22 | |
| Systolic BP (mmHg) | ||||||||||
| CON-2 | 120 ± 10 | 122 ± 10 | 121 ± 11 | 120 ± 7 | 118 ± 8 | 123 ± 9 | 122 ± 9 | 459 ± 3343 | .84 | |
| CON-6 | 118 ± 6 | 120 ± 6 | 118 ± 9 | 116 ± 6 | 121 ± 8 | 120 ± 6 | 120 ± 6 | 249 ± 2101 | −0.06 | |
| PRO-2 | 116 ± 8 | 123 ± 8 | 118 ± 11 | 118 ± 12 | 120 ± 13 | 116 ± 6 | 119 ± 8 | 1501 ± 4658 | 0.31 | |
| PRO-6 | 119 ± 8 | 119 ± 7 | 118 ± 12 | 120 ± 9 | 120 ± 7 | 118 ± 11 | 123 ± 9 | 245 ± 4209 | −0.06 | |
| Diastolic BP (mmHg) | ||||||||||
| CON-2 | 78 ± 8 | 73 ± 8 | 76 ± 9 | 78 ± 7 | 71 ± 8 | 73 ± 8 | 77 ± 5 | −1560 ± 2399 | .86 | |
| CON-6 | 76 ± 6 | 76 ± 9 | 74 ± 7 | 73 ± 6 | 73 ± 4 | 76 ± 7 | 75 ± 6 | −614 ± 2272 | −0.39 | |
| PRO-2 | 78 ± 9 | 75 ± 5 | 74 ± 7 | 75 ± 9 | 77 ± 14 | 72 ± 8 | 77 ± 8 | −1466 ± 3024 | −0.04 | |
| PRO-6 | 79 ± 6 | 77 ± 10 | 76 ± 6 | 76 ± 6 | 76 ± 8 | 76 ± 8 | 77 ± 6 | −1473 ± 2642 | −0.04 |
All values are mean ± standard deviation. n = 10. iAUC: Incremental Area under the Curve for 8.5 h period. D: Effect size Cohen’s d, Glass’sΔ correction. Figures with differing superscript letters are significantly different: p <0.05 (after Bonferroni correction)
Total Urinary Excretions of 5-F2t-isoprostanes, 15-F2t-isoprostanes Metabolites and Creatinine over 8.5 h postprandial period
| CON-2 Mean (SD) | CON-6 Mean (SD) | PRO-2 Mean (SD) | PRO-6 Mean (SD) | Overall p (ANOVA) | |
|---|---|---|---|---|---|
| 5-F2t-isoprostanes (μg) | 7.8 (13.84) | 3.4 (3.96) | 2.0 (2.20) | 3.2 (4.94) | 0.268 |
| Sum of 15-F2t-isoprostane metabolites (μg) | 2.4 (1.50) | 3.2 (2.89) | 4.7 (2.53) | 3.4 (1.48) | 0.059 |
| Creatinine (mmol) | 4.2 (1.0) | 5.8 (1.8) | 8.4 (4.7) | 7.6 (2.8) | 0.004 |